Category

News
A novel chimeric antigen receptor (CAR) T-cell therapy induced complete and durable responses in a phase I trial involving patients with heavily pretreated multiple myeloma. Of 33 patients treated with bb2121, a B-cell maturation antigen (BCMA)-directed product, 85% achieved an objective response, reported James N. Kochenderfer, of the National Cancer Institute in Bethesda, Maryland, and...
Continue Reading
A gene therapy that tweaks the immune system might offer hope to people with blood cancer that has resisted standard treatments, a new preliminary trial suggests. The cancer, called multiple myeloma, arises in certain white blood cells. It is currently incurable, but there are treatments that can help people live with the disease for years....
Continue Reading
Originally published on Te ao Almost 20,000 New Zealanders have signed eight petitions to be presented to parliament, demanding better funding of medicines. The petitions will be formally presented to MPs on May 7, asking for 26 drugs to be funded for six diseases. The diseases include breast cancer, chronic lymphocytic leukaemia, lung cancer, non-small-cell...
Continue Reading
Researchers at the University of Alabama at Birmingham have discovered a way to prevent kidney failure from occurring in people with multiple myeloma. Paul Sanders, M.D., a nephrologist in the Division of Nephrology at UAB, found that the development of chronic, progressive kidney damage can be prevented by blocking a pathway activated in the kidney by light chains proteins...
Continue Reading
For those who are able to, including family and friends, we urge you to join us on Tuesday 7 May in Wellington to march for the RIGHT TO LIVE. We’ll be presenting our petition at the steps of Parliament to ask that the drugs that extend or improve the quality of lives are funded by...
Continue Reading
Greetings to everyone as the days draw in. We are intending to generate some heat with various planned activities over the next month. There has been considerable media attention around Pharmac and the issue of delays and lack of drug funding of novel medicines in relation to solid cancers such as breast cancer and other...
Continue Reading
Bone disease is the most frequent feature of multiple myeloma (MM) and represents a marker of end-organ damage; it is used to establish the diagnosis and to dictate the immediate need for therapy. For this reason, imaging plays a significant role in the management of MM patients. Although conventional radiography has traditionally been the standard...
Continue Reading
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Background Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on overall survival in this setting has been inconsistent...
Continue Reading
Despite data suggesting that individuals with multiple myeloma can benefit from receiving several lines of therapy, and guidelines recommending treatment after relapse, a recent European patient chart review found that only 61% of patients receive second-line treatment. The review found that factors such as old age and previous adverse events lead to physicians deciding not...
Continue Reading
1 2 3 4 5 16

Floor 7, 90 The Terrace
Wellington Central
New Zealand